



AAVPT Newsletter

**American Academy of
Veterinary Pharmacology and Therapeutics**

Volume 23, Number 2

September 2004

From the President

The Executive Committee (EC) has been quietly busy in the background this year, having met by telephone twice since the Biennial Symposium and having subcommittee work progress well. Several main items of business have been communicated to members already:

- Summarizing and reviewing outcomes from the 13th Biennial Symposium
- Planning for the 14th Biennial Symposium
- Appointing a replacement Chairman for the Awards Committee after resignation of Dr. Mark Novotny from the chair
- Responding to the JVPT Editorial Board's request to consider inclusion of toxicology.

In addition, the AAVPT received a request from the editor of a major journal to provide an opinion on the acceptability (or otherwise) of research papers submitted for publication, where the studies used test article manufactured from Bulk Chemicals, contrary to the USA regulations. The EC formed an *ad hoc* sub-committee to evaluate and respond to this request. The sub-committee comprises three Fellows, Dr. Steve Sundlof (CVM), Dr. Lauren Trepanier (Academia) and Dr. Kirby Pasloske (Industry). This subcommittee is in the final phase of composing an AAVPT position paper as a response to the Editor's request.

Improving membership access to the AAVPT for interested scientists is important for the on-going health of the Academy. The EC is still considering possible changes to the Constitution, to alter the membership categories and to modernize the way in which new members are admitted to the Academy. This has been an on-going project since Dr. Scott Brown's presidency 5 years ago. It is my wish to bring this to conclusion for presentation to the membership for vote prior to the end of my term as President.

Having EC members in 4 time-zones has made telephone conferences 'inconvenient' on occasion. Nevertheless, the AAVPT is leading the way to

development of a closer global community of veterinary pharmacologists. Several of our Fellows are active participants in the British, European and Australian sister organizations. We have also included the President of the EAVPT as a (guest) member of our Listserver, and should consider extending this courtesy to other association leaders. Improving global communication between like-minded pharmacologists is a simple way of improving our chances for rapidly and forcefully responding to issues which affect veterinary pharmacology as a discipline.

The AAVPT Listserver is now ongoing after some initial establishment hassles. Please get in touch with the Secretary/Treasurer if you have difficulty with the Listserver, or alternatively go to our website (www.aavpt.org) to use the available link for updating your Listserver settings and email address. The Listserver provides us with a tool for rapid exchange of information and is one more avenue for communication. Whether this leads us to better fulfillment of our Academy's objectives depends upon the use made of the Listserver by you as members.

The Newsletter has been published in electronic form twice this year, with a third edition due later in the calendar year. Dr. Cory Langston has enjoyed receiving input for the newsletter from many members. I would like to encourage all AAVPT members to use the newsletter for news, discussion articles, opinion pieces and controversial ideas. Between Symposia, the Newsletter can be one of our most prominent and useful tools for communication.

The Annual General Meeting of the AAVPT for 2004 occurred on Wednesday, June 9th, at 12 noon in Room 209AB, Minneapolis Convention Center. This was a short meeting only, for formal acceptance of the Executive Committee and sub-committee reports.

Ted Whittem, President

Secretary/Treasurers Report

Carol Davis

I. Membership Report

LAST YEAR DUES WERE PAID

<u>Category (Total)</u>	<u>2004</u>	<u>2003</u>	<u>2002</u>
Fellow (99)	85	10	4
Assoc. Fellows (18)	16	0	2
Student (8)	7	1	0
Dist. Fellows (29)	--	--	--
Emeritus Fellows (5)	--	--	--
Total (159)	108	11	6

Our base membership stands at approximately 159 members. The total membership has decreased from 161 members in 2003 to 159 in 2004. Total membership stands at 99 Fellows, 18 associate fellows, 8 students and 34 emeritus fellows. We have 108 members who have their dues paid for 2004 with 11 members who last paid their dues in 2003 but not this year and 6 members who have not paid since 2002. Numerous attempts have been made to contact the members in the last group to find out if they would like to continue their membership. There has not been any reply to our communications. These 6 members will be dropped from the roster if we do not receive a response to our 2005 dues announcement.

II. Journal of Veterinary Pharmacology and Therapeutics

To date we have 52 paid subscription to the journal. Journal subscriptions were \$84.00 for 2004. We have been notified that the subscription rate for the journal will be increased to \$88.00 for 2005.

III. Awards

We would like to sincerely thank the following members for their contributions to the Awards Fund in 2004: R. Claxton, S. Sundlof, W. Lance, A. Bhattacharya, K. Bowman, Joe Clark, J. Owen Clark, G. Coppic, M. Ehrich, j. Gloyd, D. Gingerich, M. Heit, A. Jernigan, D. Kochevar, C. Langston, J. Oliver, M. Papich, C. Short, R, Vulliet and J. Weissinger. For 2003, we added

\$682.00 to the Award Fund. We gave out \$500.00 for the 2003 AAVPT/ACVCP graduate student award and will give another \$500.00 this year which brings will bring the award funds to \$4656.00.

IV. Election Results

We elected two new counsel members for 2005. They are Sanja Modric and Susan Longhofer who will serve from 2004-2007.

We added 3 new members to our roster during the last year. The new fellow member is Dr. Anthony Lucas (Elanco Animal Health, Greenfield, IN). The new student members are Sara Thomasy (University of California at Davis) and Dr. Stanley Butch KuKanich (North Carolina State University).

New fellow members elected to AAVPT in June are: Dr. Thomas J. Burnett, Ph.D. (Research Scientist, Eli Lilly and Company, Greenfield, Indiana), Luis Ocampo Camberos, DVM, MS (Professor, National Autonomous University of Mexico (UNAM), Mexico City, Mexico), Sherry Cox, MS, Ph.D (Associate Professor, University of Tennessee, College of Veterinary Medicine, Knoxville, TN), Tony Mogg, DVM, Ph.D. (Senior Lecturer, Massey University, New Zealand) and BA Cuong Tu, DVM, MS (DVM Pharmaceuticals, Inc. (Ivax Corporation), Miami, Florida). Mathieu Peyrou, DVM (University of Montreal) was added as student member.

V. Listserv

There is no change in the listserv from last year. There are currently 119 names on the list. Emeritus fellows have been placed on the listserv. The listserv seems to be working except occasionally an email message will be returned undelivered requiring my time to troubleshoot and attempt to update the listings. It has not been any real headache up to now but members should update their email address whenever it changes. There is a link on our home page where members can easily update their email address. It is located at the bottom left of the home page. Members are asked to check it out.

There has been some concern voiced by some people using the listserv that they are not sure how the much the listserv is being used or whether it is working correctly as some have not seen any "chatter" on any of the messages they have sent out. This has been shared with the webmaster and he has indicated that is probably due

to how the listserv is set up. He said the listserv is set so that replies that are sent using the "Reply to" button will only send the response to the original author of the message and not to everyone else. He indicated that if you want to send the reply to everyone either he will have to program the listserv to do this automatically or everyone will need to send their replies using the "Reply to all" option. He is reluctant to set it to automatic due to a potential looping problem which would result in emails being sent back and forth and causing a ton of emails to be sent out. He recommends using the "Reply to all" button for now. I will continue to look into this situation.

I have arranged for a second listserv to be set up for fellows only. It is on line but I have not added the names to the list. This listserv will be used for balloting and voting purposes. It will be set up for limited use only (no one other than the secretary will be able to send messages). It will be used only for ballot and voting purposes. The other listserv should be used for general communication between members.

I have been working with the web master to investigate an on line ballot procedure and we have had several discussions on how we might proceed. I have shown him a couple of sites as examples of what I would like to see developed. He says it should be possible to implement something similar but it might be rather expensive to set up (he estimates about \$2700) and would have some costs associated with each ballot. I will continue to work on this effort and report to the executive counsel this fall on the various options.

Submitted May 31, 2004

AAVPT Treasurer's Report

Carol Davis

Balance in checking May 30, 2003 \$15,183.77

Deposits – May 30, 2003 – April 30, 2004

Deposits from Gingerich	18,451.65
Symposium	7,890.00
Dues/Journal/Award/Application fees	10,249.00*
AVMA Drug Topics	50.00
Sponsor deposit (France)	1218.00
Total	\$38,008.65

* Includes some outstanding 2003 dues/journal/award payments (\$850) and all 2004 dues/journal/award payments

Expenses - May 30, 2003 – April 30, 2004

Transfers to Gingerich	18,000.00
Secretary of State (2004)	5.00
Blackwell (2003 JVPT)	4160.00
Newsletters (2)	194.00
Postage, office supplies	318.00
Software (MS Publisher)	183.00
Award (2003)	500.00
Symposium expenses	6806.00
LED Award (Koritz)	1255.00
Trophy expenses	504.00
Speaker expenses	5171.00
Bank fees	22.00

Balance in Checking April 30, 2004 \$15,069.94

Outstanding liabilities

Transfer of 2004 Contributions	\$682.00
2004 AAVPT Student Award	\$500.00
Blackwell (2004)	\$4,284.00

Program Committee Report

Jane Owens Clark

On behalf of the organizing committee, it is my pleasure to provide a progress report for the 14th Biennial Symposium of the American Academy of Veterinary Pharmacology and Therapeutics Symposium which will be held in the at the Doubletree Hotel in Rockville, MD on May 16-18, 2005.

In keeping with our organization's tripartite mission, the meeting will focus on three themes - Regulatory, Research and Teaching. After full days of discussion and debate, social activities are planned including an evening activity in the DC area and the traditional AAVPT banquet.

The program will consist of morning plenary sessions followed by concurrent afternoon sessions, one each focused on Regulatory, Research and Teaching.

Our plenary speakers include many of the top international experts in the field of veterinary pharmacology. Plenary speakers confirmed to date include: Steve Sundlof, Pierre-Louis Toutain, Jim Riviere, Quintin McKellar, Steven Vaughn, William Jenkins, and Stefan Soback. The Wednesday morning session will include a very timely discussion between representatives from government, academia and industry on the the double edged sword - balancing state of the art science in our while striving to maintain an even playing field drug review process.

The afternoon breakout sessions of each day will include high-powered regulatory discussions with outstanding speakers, state of the art scientific discussions, and a review of hot-teaching topics. A partial list of afternoon speakers confirmed to date include: Bernadette Dunham, Carlos Lanusse, Cory Langston, Fabiana Landoni, Mark Papich, Mike Rathbone, Alistair Webb, Art Craigmill, Robert Walker and Tomas Martin. One of the Tuesday afternoon sessions will be devoted to the hot topic of veterinary compounding and is cosponsored by the Society of Veterinary Hospital Pharmacists and AAVPT. On the afternoon of the third day, a continuing education course will be offered on Good Laboratory Practices. This one-half day course is designed to focus on the roles and responsibilities of study personnel, study site management, local quality assurance units and the FDA in GLP studies.

In past years, the AAVPT Symposia have received sponsorship by a select few veterinary pharmaceutical companies. With our global expansion in the 14th Biennial Symposium, we hope to provide greater rewards to existing sponsors and to introduce new companies to the organization. In addition, a select group of vendors with relevance to the field of veterinary pharmacology will have display booths at the symposium.

In an effort to provide international public access, increase our exposure and provide permanently citable materials, the proceedings for our 14th Biennial Symposium will appear on and will be permanently maintained by the International Veterinary Information Service (<http://www.ivis.org/home.asp>). This new approach translates to sponsors of the AAVPT Biennial Symposium receiving permanent, international exposure of their support for our state-of-the-art meeting on veterinary pharmacology and therapeutics.

AAVPT is actively pursuing the involvement of young scientists through scheduled poster sessions. This is an opportunity for graduate students to network with the leaders in veterinary pharmacology. An editorial committee will select several meritorious abstracts for short oral presentations. Interested parties are encouraged to submit abstracts for poster displays and the oral presentations. A call for abstracts has been sent out via the listserv.

Please check the website (aavpt.org) for up to date information on the Symposium or contact Carol Davis (aavptsecretary@yahoo.com).

Program Committee Members: Marilyn Martinez, Jane Owens Clark, Pierre-Louis Toutain, Carol Davis, Cory Langston, Rob Hunter, Bernadette Dunham, Guilin Qiao, Julia Punderson, Anthony Lucas, and Ted Whitem

Abstract Guidelines for the AAVPT 14th Biennial Symposium

Anthony N. Lucas

The AAVPT 14th Biennial Symposium Program Committee invites the submission of abstracts for poster presentations at the Symposium. The Symposium is organized around scientific, teaching and regulatory themes and all abstracts that address some aspect of veterinary pharmacology and therapeutics will be considered. Abstracts will be included as a part of the Symposium Proceedings and will be published on the International Veterinary Information Service (IVIS; www.ivis.org) website.

Abstracts must be submitted by the 15th of December 2004 to Dr. Cory Langston at:

langston@cvm.msstate.edu

Abstracts must be submitted as a single document that is compatible with Microsoft Word[®] (any version for Windows). File names must be in the format of:

AAVPT 14 BS Abstract<space>first initial<space>surname<space>abbreviated title

i.e. AAVPT 14 BS Abstract C Smith PK of diazepam

The total length of the abstract must be equal to, or less than, 250 words. This word limit excludes the title, author names, degrees, board certifications, addresses, telephone numbers, email addresses and key words, all

of which must be included. The presenting Author's name must be underlined. Authors should include up to five key words. Abstracts should include only text i.e., may not contain diagrams, figures, pictures, tables or charts. If references are required, they must be listed at the end of the abstract in the following format:

1. Short C et al. *Biochem Pharmacol* 1969; 18(4):945-7
2. Davis L and Wolff W. *AJVR* 1970; 31(3):469-73

Abstracts not conforming to the AAVPT guidelines by the deadline will be disqualified from being presented at the Symposium.

Edits: Abstracts will be copy proofed by the AAVPT 14th Biennial Symposium Program Committee. The AAVPT will communicate with the author to ensure that editing will not change content or meaning. Keywords are subject to approval, and revision, by the editors. If more extensive editing is deemed necessary, the abstract will be returned for appropriate changes. If changes are made, a proof will be sent to you and you will have a short period of time to confirm that the formatting is correct; however, please note that content revision will not be allowed.

Copyright agreement: The author grants unlimited and nonexclusive copyright ownership of the materials contained in the submitted abstract to the AAVPT. Unlimited means that the author agrees that the AAVPT may use various modes of distribution, including online and CD-ROM electronic distribution formats. Nonexclusive means that the AAVPT grants to the author an unlimited right to subsequently reuse the submitted materials; except for on the internet, where the IVIS will be the only website where the abstract will be available.

Please direct questions to:

Dr. Anthony N. Lucas
Research Scientist, Pre-Clinical Biology
ELANCO Animal Health
A Division of Eli Lilly and Company
2001 West Main St., GL14
Greenfield, IN 46140
Phone 317-651-4371
Fax 317-277-4522
lucasan@lilly.com

Your *Journal of Veterinary Pharmacology and Therapeutics* continues to thrive. A few noteworthy events have occurred this year. In June, JVPT published the USP Veterinary Pharmaceutical Information Monographs on anti-inflammatories. Submissions to the journal are ahead of last year's pace and our impact factor is also on the rise. JVPT is now exploring adding drug toxicology to its subject areas, a move initiated by our European

colleagues and agreed to this year by both AAVPT and ACVCP. A special issue on toxicology will be published next year. This will increase the breath of the journal and its impact. The 2003 JVPT Best Paper Prize goes to Arthur Craigmill for his paper "A Physiologically Based Pharmacokinetic Model for Oxytetracycline Residues in Sheep" [*JVPT* 26 (1): 55-64, 2003]. Finally, your journal survives through your submissions. Please consider us when you publish your next work.

AAVPT Awards Committee

Anthony Lucas

The AAVPT awards committee for 2004 consists of Lauren Trepanier, Craig Parks and Anthony Lucas. The objectives of the committee are to request nominations and select recipients for the five AAVPT awards. The awards are the Lloyd E. Davis Award, the AAVPT Service Award, the AAVPT Teaching Award, the AAVPT Research Award and the Resident/Graduate Student Pharmacology Research Award. Information on each of these awards and a list of previous recipients can be found on the AAVPT website (www.aavpt.org).

At the ACVIM Conference in Minneapolis in June 2004, Dr. Jennifer L. Davis from the North Carolina State University College of Veterinary Medicine was awarded the ACVCP/AAVPT Resident/Graduate Student Pharmacology Research Award. The winning presentation was entitled, "The Pharmacokinetics of itraconazole in the horse", and was chosen from five abstracts from three graduate students. Congratulations to Dr. Davis and thanks to Drs. Deborah Kochevar and Katrina Mealey for their assistance in judging the award.

For 2005, it is hoped that all five awards will be presented at the 14th Biennial AAVPT Symposium in Washington DC, May 16-18, 2005. A request for nominations for each award will be circulated shortly via the AAVPT website and newsletter and we look forward to your thoughtful responses to this opportunity to publicly acknowledge the outstanding contributions of a

Journal of Veterinary Pharmacology and Therapeutics (JVPT)

Jim E. Riviere

wide range of members of the veterinary pharmacology community.

Liaison reports

USP Drug Information: *Cory Langston*

In June of 2004 the USP Veterinary Medicine Drug Information Expert Committee published a supplement to JVPT specific to veterinary anti-inflammatory use. This follows a similar series on veterinary antimicrobials published last fall. All monographs are available for public use at www.usp.org (follow veterinary links).

ACVCP: *Terry Clark*

The American College of Veterinary Clinical Pharmacology certified seven diplomates following the certification examination held in Minneapolis, Minnesota on June 7-8, 2004.

The new diplomates are Dr. Lara Maxwell, Stillwater, Oklahoma; . Dr. Butch Kukanich, Garner, North Carolina; Dr. Sarah Wagner, Fargo, North Dakota; Dr. Virginia Fajt, Pueblo, CO; Dr. Ron Johnson, Kalamazoo, MI; Dr. Eden Bermingham, Georgetown, Delaware; and Dr. Gary Magdesian, Vacaville, California.

AVMA – Council on Biologics and Therapeutics (COBTA): *Dawn Boothe*

Much of the activities of COBTA this year focused on issues related to prescribing and dispensing drugs. Major activities included:

1. Discussion of providing to the AVMA recommendations regarding internet / compounding pharmacy sponsorship of the AVMA convention (in light of potential illegal activities that might be followed by the pharmacies)
2. Generation of a “Principles of the Prescribing and Dispensing of Drugs in Veterinary Patients” ; the portion of this document that focuses on compounding is being modified with the intent of being published in the JAVMA.
3. Discussion (ongoing) of the impact of the new compliance policy guide for compounding of animal drugs on the profession, particularly as it pertains to compounding from bulk substances. The Council is in dialogue with the International Academy of

Compounding Pharmacies and with the Food and Drug Administration (CVM) regarding mechanisms through which the CPG might be changed such that flexibility is provided for compounding from bulk substances for non-food animals when medically necessary while not compromising the FDA’s ability to regulate inappropriate compounding, including compounding from bulk substances of drugs intended for use in Food Animals. COBTA does not support the repeal of the new CPG but supports modification to be pursued. Discussion also has focused on changes in (expansion of) Appendix A or the generation of a “negative” [do not compound from bulk substances] list of drugs.

4. Discussion (ongoing) with JAVMA regarding publication policy as it relates to acceptance versus rejection of reports whose methods involve the practice of activity perceived to be “illegal” (i.e., formulation of a transdermal gel using a bulk substance).
5. Discussion, in conjunction with the National Association of State Pharmacy Boards of a Verification of Internet Pharmacies Program (VIPPS); and with the American College of Veterinary Clinical Pharmacy regarding a certification program (based on coursework, experience and examination) for pharmacists that have demonstrable expertise in veterinary pharmacy.
6. Continued examination of mechanisms whereby reporting of adverse events to all medicinal agents might be improved in veterinary medicine. The most recent focus has been more in depth dialogue with the ASPCA’s Animal Poison Control Center in an attempt to identify means whereby the activities of the APC might be expanded to address the needs of the profession regarding reporting of adverse events.

Cory Langston joined the COBTA as the Clinical Pharmacology representative.

News

Once daily oral cephalosporin to treat skin infections in dogs

(Extracted from the FDA News)

The Food and Drug Administration has approved a new antibiotic drug for dogs, giving veterinarians a new once daily treatment option to treat skin infections (wounds and abscesses) which are common problems among dogs.

The product is called "Simplicef[®]" (cefprozime proxetil), developed by Pharmacia & Upjohn Co., of Kalamazoo, Michigan, a division of Pfizer, Inc. The drug is an extended spectrum cephalosporin that is effective in the treatment of skin infections in dogs caused by susceptible strains of *Staphylococcus intermedius*, *Staphylococcus aureus*, *Streptococcus canis*, *Escherichia coli*, *Pasteurella multocida*, and *Proteus mirabilis*. ... The drug is a film-coated tablet given to the dog orally once a day. It will be available by veterinarian prescription starting this fall.

Insulin for Dogs

(Extracted from the FDA News)

The Food and Drug Administration's Center for Veterinary Medicine has approved an insulin product for treatment of diabetes in dogs, making it the first diabetes drug approved for animals. The drug's sponsor, Intervet, Inc., Millsboro, Del., earlier this year received approval to begin marketing a drug for use in dogs to treat the clinical signs of diabetes, which include excessive thirst, urination and appetite, along with weight loss despite a good appetite. Intervet's product, called Vetsulin[®], is made from porcine insulin.

Antiprotozoal for EPM

(Extracted from the FDA News)

Nitazoxanide oral paste (Navigator[®]) by IDEXX Pharmaceuticals has been approved for the treatment of equine protozoal myeloencephalitis (EPM) caused by *Sarcocystis neurona*.

Topical Anti-Inflammatory Cream for Horses Approved

(Extracted from IDEXX news release)

IDEXX Laboratories announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market and sell SURPASS[™] (1% diclofenac sodium) Topical Anti-Inflammatory Cream, a new treatment for horses with pain and lameness due to osteoarthritis. SURPASS topical cream represents the first equine pharmaceutical use of a topical liposomal formulation of the FDA-approved nonsteroidal anti-inflammatory drug, diclofenac. The product is labeled as a veterinary-only prescription medication to be used under the supervision of a licensed, practicing veterinarian.

Minor Use and Minor Species (MUMS) Animal Health Act signed

(Extracted from the AVMA News)

President Bush signed into law on Aug. 2 legislation that will increase the number of approved animal drugs for species and ailments for which treatment options have traditionally been limited.

Similar to the program created in 1983 by the Human Orphan Drug Act, which increased the availability of drugs for rare human diseases, the new MUMS law offers pharmaceutical companies incentives to develop drugs for uncommon diseases in major animal species and diseases in minor species.

Minor species encompasses thousands of animal species, including fish and sheep. Minor uses are drug treatments for animal diseases that occur infrequently or in limited geographic areas in any animals.

A critical shortage of approved animal drugs for minor uses and minor species exists because of limited sales opportunity, low profit margins, and the high capital investment necessary for bringing a drug to market.

The MUMS legislation creates the Office of Minor Use and Minor Animal Species Drug Development within the Food and Drug Administration. Its mission is to issue grants, determine eligibility for listing on the drug index, and serve as a liaison among government agencies to improve opportunity for drug approvals.

Furthermore, the FDA is authorized to promulgate regulations allowing drug applications for minor species and minor uses to receive conditional approval when a drug is demonstrated to be safe and have a reasonable expectation of efficacy. This conditional approval, evaluated annually, would be limited to five years, until full approval is achieved.

Additionally, the law establishes a category of index drugs that can be used to treat nonfood minor species in cases when conditional approval is not economically feasible. Most importantly, the legislation makes it legal for veterinarians to use such drugs.

Approval Of 3-Year Duration Of Immunity Canine Distemper, Parvo, And Adenovirus Vaccine Based On Challenge Studies.

(Extracted from Fort Dodge news release)

Fort Dodge Animal Health announces the approval of Duramune® Adult, the first USDA licensed vaccine

with three-year virus challenge data against a trio of deadly canine diseases - canine parvovirus (CPV), canine distemper (CDV) and canine adenovirus (CAV). The new vaccine will be available in the second quarter of 2004.

Duramune Adult will provide veterinarians with the product they have been asking for - a vaccine with extended duration of immunity data based on controlled challenge studies. For the first time, the USDA has approved a vaccine that is particularly well suited as a booster for adult dogs if an extended vaccination interval program is being utilized.



AAVPT Newsletter Staff

Editor: Cory Langston

The Newsletter is published twice yearly by the

American Academy of Veterinary Pharmacology and Therapeutics. Please kindly address all correspondence to: Dr. Cory Langston; College of Veterinary Medicine; PO Box 6100; Miss. State, MS 39762-6100; USA; email: langston@cvm.msstate.edu.

Dr. Cory Langston
College of Veterinary Medicine
PO Box 6100
Mississippi State, MS 39762-6100